X
J&J preps for FDA panel grilling over depression drug
https://pharmaphorum.com/news/janssen-preps-for-fda-panel-grilling-esketamine/
depression
J&J files esketamine nasal spray antidepressant in US
Drug targets 30% of people who don’t respond to approved treatments
Mixed phase 3 results from J&J’s esketamine depression drug
Drug missed efficacy endpoint in older population
Allergan and Gedeon Richter set to expand use of bipolar drug
Companies want Vraylar as option bipolar depression
Takeda depression app impresses in pilot study
App corresponds with standard cognitive and patient-reported assessment measures.
Lundbeck trial investigates genetic causes of depression
New study with 23andMe and Milken Institute looks to determine causes of depression.
US researchers create AI capable of diagnosing depression
Algorithm accurately detects depression from brain scans in 75% of cases.
Takeda to pilot wearable-based depression app
Cognition Kit wearable app measures daily activities and tests cognitive function.
1 2
